CHEK1 and breast cancer: We previously found no additivity/synergy between xentuzumab and ATR inhibition in MCF7 [14], and confirm here that ATR inhibition was not a hit in any of the 5 screened breast cancer cell lines, while in contrast we find evidence of synergy with CHK1 inhibition.